Versartis (VSAR) is preparing to present phase 3 trial data on its lead compound in the coming months.
There are three companies currently developing long acting versions of growth hormone - Versartis (VSAR), Opko Health (OPK) and Ascendis (ASND).clinical data drug hGH patient Phase product somavaratan trial Versartis
Here I discuss my investment thesis, citing forecasted growth, its strong track record in all environments and key valuation measures.
In February, I wrote an article on SA discussing my investment in Wyndham (NYSE:WYN), and comparing the company to Choice Hotels (CHH), WYN's closest peer.CHH choice hotel past RevPAR room royalty stock WYN year
Before a telecom company can expand into what it sees as the more lucrative cable or content production markets, it needs scale. CEO Marcelo Claure thinks so, but he also believes that combining with another wireless carrier or a cable company would make a stronger company.cable charter Communications Corp Inc merger mobile NASDAQ NYSE Sprint
By Kevin O'Hanlon LINCOLN, Neb.
FTS International has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
FTS has a 1.6 million total hydraulic horsepower across 32 fleets, with 25 fleets active as of August 1, 2017.Exchange fleets FTS hydraulic intends offering resource services Shale unconventional
Often companies will post solid results and investors sell the shares anyway, and that plays right into the time-honored Wall Street axiom of “Buy the rumor, and sell the news.” While in many cases that is not bad advice, especially in the current stock market that is trading at nosebleed multiples, it does make sense to look at each company and its commentary for clues to what’s coming up, not what has been completed.
The analysts at SunTrust Robinson Humphrey said just that in a series of recent reports by urging clients to jump on the shares of two companies that displayed weakness, despite either solid results or investors not looking at the tailwinds that could push prices higher down the road.companies game PVC results Solid stock SunTrust Vinyls Wall Street Westlake
As a result, CVR Energy, the company through which Icahn is making the bet, has booked a nearly $280 million liability. If things keep going this way, the liability could eat into CVR Energy's cash pile, leaving it with less money to distribute to shareholders.biofuel Blend credits CVR energy Icahn liability obligation refiner refining
Surmodics, Inc. SRDX reported earnings of 9 cents per share in third-quarter fiscal 2017, much lower than the year-ago figure of 37 cents.
Surmodics reports revenues under two segments - Medical Device and In Vitro Diagnostics (IVD).cents earnings fiscal growth Medical quarter Revenue sales stock Surmodics
WellCare Health Plans, Inc. WCG reported second-quarter 2017 adjusted operating earnings of $2.52 per share that surpassed the Zacks Consensus Estimate of $2.23 by 13%. The upside was primarily driven by the premium revenue growth in the company's Medicaid Health Plans and Medicare Health Plans segments and continued operational execution.due growth Health Plans Medicare membership premium revenue primarily quarter year Zacks
Shares of STMicroelectronics (NYSE: STM) climbed 17.7% in July, according to data from S&P Global Market Intelligence , as investors grew more optimistic that the company would deliver strong second-quarter results -- which it did.
STMicroelectronics rebounded in July after seeing its stock price fall nearly 13% in June on analysts' worries that tech stocks may be overdue for a correction .Fool global investors July market Motley quarter Revenue STMicroelectronics stock
Amazon (NASDAQ: AMZN) stock sold off after its second quarter results, likely because earnings per share of $0.40 missed expectations by a whopping 72%. Not only that, but Amazon guided for operating income of negative $400 million to $376 million next quarter, versus consensus estimates of positive $950 million.Amazon cloud growth increased market Motley Fool NASDAQ quarter service shares
Having your shares in a company heavily diluted by a big secondary share issue is often scary for investors.
Spark Therapeutics is issuing just over 4.6 million shares of newly issued common stock at $76 per share.announced Biotech drug investors issue market results shares Spark Therapeutics stock